logo
Plus   Neg
Share
Email

Seattle Genetics To Receive $30 Mln Milestone Payment From Takeda - Quick Facts

Seattle Genetics, Inc. (SGEN) announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing authorization for ADCETRIS (brentuximab vedotin) to include ADCETRIS in combination with AVD (Adriamycin, vinblastine and dacarbazine) in adults patients with previously untreated CD30+ stage IV classical Hodgkin lymphoma. Seattle Genetics will receive a milestone payment from Takeda of $30 million for the European Commission approval.

Clay Siegall, CEO at Seattle Genetics, said: "We look forward to continuing our work with Takeda to establish ADCETRIS as the global foundation of care for CD30-expressing lymphomas, including Hodgkin lymphoma."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Boeing said Sunday that it had informed the Federal Aviation Administration and international regulators on multiple occasions about the expanded role of the flight-control software in 737 MAX, which was linked to two fatal crashes that killed 346 people. The U.S. Department of Justice has reached a settlement agreement with a Texas-based Taco Bell franchise owner for immigration-related discrimination against certain employees. The settlement resolves the DOJ's investigation into whether MUY Brands LLC, and a related management company, MUY Consulting Inc., violated the Immigration and Nationality Act. Starbucks is gearing up for the upcoming holiday season by introducing its 2019 holiday flavors in U.S. grocery stores. The launch of the coffee giant's holiday line-up this year includes returning holiday favorites as well as a new item. Customers can now take home products that are making a comeback such as Starbucks Holiday Blend K-Cup and Ground Coffee, Peppermint Mocha Flavored Ground Coffee,
RELATED NEWS
Follow RTT
>